A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02611323 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: Obinutuzumab
DRUG: Rituximab
DRUG: Polatuzumab Vedotin
DRUG: Venetoclax

Sponsor

Hoffmann-La Roche